[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prehypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prehypertension":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,71,95,125,146,182,210],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100639837","a-clinical-trial-of-an-herbal-liquid-supplement---dbps-for-managing-blood-pressure-100639837",false,"NCT07629570","A Clinical Trial of an Herbal Liquid Supplement - 'DBPS' for Managing Blood Pressure","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of DOSE for Blood Pressure Shot (DBPS) in Prehypertensive Subjects.","Inclusion Criteria:\n\n1. Men and women between the ages 18 and 65 years, inclusive, at the time of signing the informed consent.\n2. Seated clinic systolic blood pressure (SBP) in the range of 120 to 139 mm Hg and diastolic blood pressure (DBP) in the range of 80 to 89 mmHg confirming a prehypertensive state as per JNC 7 and WHO guidelines.\n3. In good general health as determined by a medical history, physical examination, vital signs, electrocardiogram (ECG), and routine clinical laboratory tests (hematology, clinical chemistry, urinalysis).\n4. Body Mass Index less than 30 kg\u002Fm2.\n5. Women of childbearing potential (WOCBP) must agree to use a highly effective method of contraception (e.g., oral contraceptives, intrauterine device, barrier methods with spermicide, surgical sterilization) from screening until the end of the study. Women who are postmenopausal (defined as amenorrhea for at least 12 consecutive months) or surgically sterile are eligible.\n6. Provide written informed consent to participate in the study after all procedures have been fully explained and questions answered.\n7. Willing and able to comply with all study procedures, visit schedules, and restrictions.\n\nExclusion Criteria:\n\n1. Diagnosed with Stage 1 Hypertension (SBP more than 139 mmHg or DBP more than 89 mmHg or Stage 2 Hypertension as per JNC 7 and WHO guidelines\n2. Evidence of secondary hypertension (e.g., renal artery stenosis, primary hyperaldosteronism, sleep apnea).\n3. History of significant cardiovascular disease, including but not limited to:\n\n   (i) Myocardial infarction, stroke, or transient ischemic attack within the past 6 months.\n\n   (ii) Symptomatic heart failure or left ventricular ejection fraction less than 40%.\n\n   (iii) Cases of class III and class IV congestive heart failure (CHF) as defined by the New York Heart Association.\n\n   (iv) Unstable angina pectoris or revascularization procedure within the past 3 months.\n\n   (v) Significant valvular heart disease or complex congenital heart disease by medical history.\n4. Use of any medications (prescription, over-the-counter, herbal supplements, certain vitamins\u002Fminerals) known to affect blood pressure or interfere with study product absorption\u002Fmetabolism within 14 days prior to the dosing visit, or unwillingness to stop them for the study duration.\n5. Organ Function Impairment:\n\n   (i)Impaired hepatic function (Alanine aminotransferase \\[ALT\\] or Aspartate aminotransferase more tan 2 times the upper limit of normal \\[ULN\\]).\n\n   (ii)Impaired renal function (serum creatinine level more than 132.6 μmol\u002FL or estimated Glomerular Filtration Rate \\[eGFR\\] less than 60 mL\u002Fmin\u002F1.73m2).\n\n   (iii) Serum potassium outside the normal range (less than 3.5 mmol\u002FL or more than 5.5 mmol\u002FL).\n6. History of uncontrolled diabetes mellitus (e.g., HbA1C level more than 7.0% and\u002For FBS more than 125mg\u002FdL or use of diabetes medications).\n7. Any chronic diseases that may interfere with study participation or pose additional risk to the subject.\n8. A tobacco smoker or user of nicotine products in the 6 months prior to screening.\n9. Excessive alcohol consumption (Men more than 14 drinks\u002Fweek and women more than 7 drinks\u002Fweek).\n10. History of substance abuse or dependency within the last 1 year.\n11. Women who are pregnant or lactating.\n12. History of hypersensitivity or contraindication to the test product (DBPS) or any of its components or placebo.\n13. Participation in another clinical research study involving an investigational product within 30 days prior to screening or during the current study.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},198,"ESTIMATED","INTERVENTIONAL",[25],"NA","Prehypertension is a clinical condition characterized by systolic blood pressure (SBP) readings between 120 and 139 mmHg and\u002For diastolic blood pressure (DBP) readings between 80 and 89 mmHg, as per the Joint National Committee (JNC 7) and World Health Organization (WHO) guidelines. Individuals falling within this range do not yet meet the criteria for hypertension but are at a significantly elevated risk of progressing to full-blown hypertension and developing associated cardiovascular diseases such as heart attack and stroke. This stage is considered as a critical window for intervention, as timely and appropriate measures can potentially halt or delay the progression to more severe health issues.",[28],"Prehypertension",[30],"Elevated Blood Pressure","NOT_YET_RECRUITING","2026-06-01",{"date":34,"type":35},"2026-06-05","ACTUAL",{"date":37,"type":22},"2026-05-15",{"date":39,"type":22},"2026-08-30",{"name":41,"class":42},"Eetho Brands, Inc","INDUSTRY",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100621600","smartwatch-based-intervention-for-cardiovascular-health-switch-100621600","NCT07372729","Smartwatch-based Intervention for Cardiovascular Health (SWITCH)","A Smart Wearable Devices-based Comprehensive Intervention Through a Cluster Randomized Controlled Trial to Improve Cardiovascular Health in Overweight\u002FObese Individuals With Cardiometabolic Preconditions","Inclusion Criteria:\n\n1. Age \\>= 18 years, no gender restriction;\n2. Overweight and obesity: Body Mass Index (BMI) 24.0-32.4 kg\u002Fm\\^2, or waist circumference \\>= 90 cm for males and \\>= 85 cm for females;\n3. Presence of at least one metabolic high-risk state among prehypertension, prediabetes, or borderline elevated blood lipids, and without a diagnosis of hypertension, diabetes mellitus, or dyslipidemia:\n\n(1) Prehypertension: Systolic blood pressure (SBP) 130-139 mmHg and\u002For diastolic blood pressure (DBP) 80-89 mmHg, without regular use of antihypertensive medication in the past month; (2) Prediabetes: Fasting blood glucose (FBG) 6.1-6.9 mmol\u002FL, or glycated hemoglobin (HbA1c) 5.7%-6.4%, without regular use of hypoglycemic medication in the past month; (3) Borderline elevated blood lipids: Total cholesterol (TC) 5.2-6.1 mmol\u002FL, or low-density lipoprotein cholesterol (LDL-C) 3.4-4.0 mmol\u002FL, or triglycerides (TG) 1.7-2.2 mmol\u002FL, or non-high-density lipoprotein cholesterol (non-HDL-C) 4.1-4.8 mmol\u002FL, without regular use of lipid-lowering medication in the past month; 4. Local permanent residents who will reside in the area for at least 12 month after enrollment; 5. Have basic reading, writing, and comprehension abilities; proficient in using internet-connected smartphones; able to independently complete basic operations of the application; 6. Written informed consent provided.\n\nExclusion Criteria:\n\n1. Secondary obesity diagnosed by doctors in secondary or higher-level medical institutions;\n2. Cardiovascular and cerebrovascular diseases, including myocardial infarction, stroke, heart failure, arrhythmia; or having received coronary intervention therapy, cardiac surgery, etc.; or with a 10-year high risk of cardiovascular disease;\n3. Diseases seriously affecting survival, such as malignant tumors, AIDS, hepatic and renal failure;\n4. Pregnancy, lactation period, or women who may become pregnant within one year;\n5. History of severe neuropsychiatric diseases with potential cognitive or communication impairments, such as dementia, Alzheimer's disease, Parkinson's syndrome;\n6. Individuals with limited daily mobility;\n7. Individuals undergoing or planning to receive weight loss through surgery, medication, or other methods;\n8. Currently participating in other lifestyle intervention-related trials.",{"count":52,"type":22},1400,[25],"This study aims to employ a cluster randomized controlled trial to evaluate the effectiveness of an mHealth-Based Multi-faceted Cardiovascular Health Intervention Model among Overweight\u002FObese Individuals with Cardiometabolic Preconditions, thereby providing theoretical foundations and practical guidance for the prevention and management of this population.",[28,56,57,58],"Borderline Dyslipidemia","Overweight , Obesity","Prediabetes","RECRUITING","2026-05-12",{"date":62,"type":35},"2026-05-14",{"date":64,"type":35},"2026-03-24",{"date":66,"type":22},"2027-03-15",{"name":68,"class":69},"Beijing Anzhen Hospital","OTHER",3,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":78,"minAge":18,"maxAge":19,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100630946","efficacy-of-nigella-sativa-nisatol-in-women-with-borderline-blood-pressure-values-or-a-non-dipper-blood-pressure-phenotype-100630946","NCT07494279","Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype","Efficacy of Nigella Sativa (Nisatol®) Supplementation in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype: A Randomized Placebo-Controlled Study With Dietary Intervention Phase","Inclusion Criteria\n\n* Female participants\n* High-normal blood pressure values (≥130\u002F85 mmHg) or mild hypertension (140\u002F90 mmHg) with low cardiovascular risk and no current indication for pharmacological therapy\n* Presence of a non-dipper blood pressure phenotype on 24-hour ambulatory blood pressure monitoring\n* Absence of antihypertensive pharmacological treatment Exclusion Criteria\n* History of cardiovascular disease\n* Diabetes mellitus\n* Severe chronic diseases\n* Use of medications affecting blood pressure or heart rate\n* Known allergy to Nigella sativa or fennel","FEMALE",{"count":80,"type":22},106,[25],"This randomized placebo-controlled study evaluates the efficacy of Nigella sativa (Nisatol®) supplementation in women with borderline blood pressure values or a non-dipper blood pressure phenotype. The study aims to assess the effects of supplementation on blood pressure and resting heart rate in women presenting high-normal blood pressure values (≥130\u002F85 mmHg) and\u002For a nocturnal non-dipper blood pressure pattern.\n\nParticipants will be randomly assigned to receive either Nigella sativa (Nisatol®) or placebo for 12 weeks. After the treatment phase, a washout period will be followed by a dietary intervention phase combined with alternate treatment according to the study design. Cardiological and nutritional assessments will be performed at predefined time points.",[28,84],"Hypertension","2026-03-20",{"date":87,"type":35},"2026-03-27",{"date":89,"type":22},"2026-03-30",{"date":91,"type":22},"2026-12-31",{"name":93,"class":69},"Liaquat University of Medical & Health Sciences",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100619278","guided-physical-activity-counseling-for-hypertension-in-primary-care-100619278","NCT07342543","Guided Physical Activity Counseling for Hypertension in Primary Care","Inclusion Criteria for Providers:\n\n1. Currently work for UC San Diego Health, with a primary appointment in one of the eight primary care clinics\n2. Conduct ambulatory care visits for blood pressure management with at least 20 patients with a diagnosis of pre- or stage 1 hypertension\n\nInclusion Criteria for Patients:\n\n1. Have received a diagnosis of pre- or stage 1 hypertension, and\u002For having SBP 120-139, DBP \\\u003C89\n2. be receiving care from one of the enrolled providers\n3. be currently engaging in \\\u003C150 minutes\u002Fweek of at least moderate intensity exercise (see below)\n4. be between age 18 and 80 years\n5. not currently taking anti-hypertensive medication\n6. able to read, speak, and understand English.\n\nExclusion Criteria for Providers:\n\n1. planning to leave UCSD Health in the next 18 months\n2. participated in the co-design workshops to design the PACE system\n3. being unwilling to be randomized to one of the three conditions.\n\nExclusion Criteria for Patients:\n\n1. any condition that would contraindicate unsupervised exercise as determined by their provider, such as severe cardiovascular or pulmonary disease limiting exercise tolerance\n2. plans to change healthcare providers within the next two months\n3. planned surgery or procedure that could impact mobility within the next five months\n4. pregnancy.","80 Years",{"count":103,"type":22},330,[25],"The goal of this study is to create easy-to-read physical activity reports and counseling guides for primary care doctors. These tools will use activity data collected over time from wearable fitness trackers. The study will also test how helpful and easy the system is for doctors when talking with patients who have high blood pressure. This approach uses technology that already exists and helps solve problems that make it hard to use in medical care. It also has the potential to reach many people and be low-cost for clinics to use.",[107,84,28,108],"Physical Activity","Hypertension Grade I, Subgroup \"Borderline\" (WHO)",[110,111,112,113,114,115],"primary care","physical activity counseling","fitness tracker","physical activity","prehypertension","stage 1 hypertension","2026-01-13",{"date":118,"type":35},"2026-01-15",{"date":120,"type":22},"2026-10-01",{"date":122,"type":22},"2031-01-01",{"name":124,"class":69},"University of California, San Diego",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":94},"100180746","sympathetic-overactivity-in-post-traumatic-stress-disorder-100180746","NCT01627301","Sympathetic Overactivity in Post-traumatic Stress Disorder","Mechanisms of Sympathetic Overactivity in Post-traumatic Stress Disorder","SO-PTSD","Inclusion Criteria:\n\n* prehypertensive and normotensive veterans with PTSD, and prehypertensive and normotensive veterans without PTSD (controls)\n\nExclusion Criteria:\n\n* heart or vascular disease\n* illicit drug use within the last 6 months\n* excessive alcohol use (\\>2 drinks per day)\n* pregnancy\n* autonomic dysfunction\n* medications known to affect SNS (clonidine)\n* treatment with monoamine oxidase (MAO) inhibitors within the last 14 days\n* any serious systemic disease",{"count":134,"type":22},120,[25],"Post-traumatic stress disorder (PTSD) is a highly prevalent anxiety disorder that is associated with an increased risk of cardiovascular (CV) disease and hypertension. One potential mechanism is overactivation of the sympathetic nervous system (SNS), both at rest and particularly during stress. This study will evaluate whether 8 weeks of daily DGB therapy or transcutaneous vagus nerve stimulation (tVNS) therapy improves SNS activity at rest and during stress.",[138,28],"Post-traumatic Stress Disorder",{"date":118,"type":35},{"date":141,"type":35},"2012-07",{"date":143,"type":22},"2027-12",{"name":145,"class":69},"Emory University",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":16,"sex":17,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":158,"conditions":159,"keywords":164,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":94},"100561907","community-park-based-programs-for-health-promotion-the-fit2lead-prospective-cohort-study-100561907","NCT06596265","Community Park-Based Programs for Health Promotion: The Fit2Lead Prospective Cohort Study","F2L","Inclusion Criteria:\n\n* All participants enrolled in the Miami-Dade Fit2Lead study will be included in this secondary analysis\n* Aged 12-17 years, residing in Miami-Dade County\n\nExclusion Criteria:\n\n* Anyone not enrolled in the Miami-Dade Fit2Lead study will be excluded from this secondary analysis\n* Aged \\<12 or \\>17 years, not residing in Miami-Dade County, cannot read and speak in English","12 Years","17 Years",{"count":156,"type":22},1000,"OBSERVATIONAL","The Fit2Lead prospective cohort study examines the effects of a park-based youth mental health and resilience afterschool program on youth participant mental health, resilience, physical fitness, and violence prevention outcomes. Duke will perform a secondary analysis of the data collected as part of the Fit2Lead prospective cohort study run by Miami-Dade County Parks and Recreation.",[160,161,162,84,28,163],"Anxiety","Wellness, Psychological","Overweight or Obesity","Low Physical Fitness",[165,166,167,168,169,170,171,172],"Youth","Adolescent","Afterschool","Parks and Recreation","Mental Health","Physical Helath","Resilience","Violence Prevention","2025-09-03",{"date":175,"type":35},"2025-09-10",{"date":177,"type":35},"2016-02-17",{"date":179,"type":22},"2028-06-17",{"name":181,"class":69},"Duke University",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":16,"sex":17,"minAge":189,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":193,"conditions":194,"keywords":200,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":94},"100561829","community-park-based-programs-for-health-promotion-fit2play-prospective-cohort-study-100561829","NCT06595251","Community Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study","F2P","Inclusion Criteria:\n\n* All participants enrolled in the Miami-Dade Fit2Play study will be included in this secondary analysis\n\nExclusion Criteria:\n\n* Anyone not enrolled in the Miami-Dade Fit2Play study will be excluded from this secondary analysis","6 Years","14 Years",{"count":192,"type":22},5000,"The Fit2Play prospective cohort study examines the effects of a park-based youth physical activity afterschool program on youth participant fitness and mental health outcomes. Duke will perform a secondary analysis of the data collected as part of the Fit2Play prospective cohort study run by Miami-Dade County Parks and Recreation.",[195,196,84,28,160,197,198,163,199],"Overweight","Obesity","Well-being","Depression","Psychological",[165,167,168,169,201,107,202],"Physical Health","Exercise",{"date":204,"type":35},"2025-09-04",{"date":206,"type":35},"2020-05-07",{"date":208,"type":22},"2027-05-17",{"name":181,"class":69},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":217,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":94},"100306063","phase-4-intervention-for-high-normal-blood-pressure-in-adults-with-type-2-diabetes-100306063","NCT03264352","Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes","IPAD","Inclusion Criteria:\n\n* irrespective of sex;\n* aged between 45 and 79 years;\n* with office-measured seated BP 120-139 mm Hg systolic and below 90 mm Hg diastolic;\n* diagnosed of type 2 diabetes mellitus (T2DM), currently on diabetic therapy;\n* informed consent provided and long-term follow-up possible\n\nExclusion Criteria:\n\n* poor control of blood glucose, HbA1c \\> 10.0%\n* administration of any antihypertensive medications within 1 month;\n* a history of hypoglycemic coma \u002F seizure;\n* confirmed diagnosis of type 1 diabetes mellitus;\n* alanine-aminotransferase (ALT) or aspartate-aminotransferase (AST) over three times the upper limit of normal;\n* estimated glomerular filtration rate \\\u003C 45 ml\u002Fmin\u002F1.73m2;\n* a history of congestive heart failure with left ventricular ejection fraction \\\u003C 40%;\n* coronary artery disease requiring RAS blockers for secondary prevention;\n* acute on-set of stroke within 6 months prior to randomization;\n* a ratio of urinary albumin (in mg\u002FL) to urinary creatinine (in g\u002FL) (ACR) ≥ 300 mg\u002Fg;\n* known contraindications for the active study medications;\n* a history of psychological or mental disorder;\n* pregnancy or currently planning to have babies or lactation;\n* severe diseases such as severe heart diseases;\n* an expected residual life span less than 3 years;\n* a malignancy that clinical investigators consider as unsuitable to participate;\n* currently participating in another clinical trial.","45 Years","79 Years",{"count":220,"type":22},11414,[222],"PHASE4","Lowering of blood pressure (BP) in high-risk hypertensive individuals reduces major adverse cardiovascular and cerebrovascular events. Diabetic patients with hypertension benefit from BP lowering treatment. The present trial, IPAD in brief, is a randomized, open-label, parallel-designed, multicenter study involving nearly 12,000 patients to be recruited and to be followed up for a median of four years. IPAD tests the hypothesis that antihypertensive medications in adults with type 2 diabetes, whose seated BP 120-139 mm Hg systolic and below 90 mm Hg diastolic, results in 20% difference in the incidence of major adverse cardiovascular and cerebrovascular events. During follow-up for participants in the intensive group, the sitting systolic pressure should be decreased to below 120 mm Hg, by titration and combination of the study medications of an angiotensin type-1 receptor blocker Allisartan (240 mg\u002Fday), a dihydropyridine calcium-channel blocker (amlodipine 5-10 mg\u002Fday), and\u002For other medications if necessary. For those in the standard group, the sitting systolic pressure should be monitored and controlled below 140 mm Hg.",[225,226,227,28,228],"Diabetes Mellitus, Type 2","Adverse Event","Blood Pressure","Cardiovascular Risk Factor","2025-03-10",{"date":231,"type":35},"2025-03-12",{"date":233,"type":35},"2018-02-01",{"date":235,"type":22},"2025-09",{"name":237,"class":69},"XueQing Yu"]